New allergy drug shows promise in early trial
NCT ID NCT07254871
First seen Jan 11, 2026 · Last updated May 20, 2026 · Updated 21 times
Summary
This study tests an experimental treatment called DM-101PX to see if it can safely reduce allergy symptoms caused by birch pollen. About 100 adults with birch pollen allergy will receive either the treatment or a placebo. The main goal is to measure changes in nasal symptoms like sneezing and stuffiness after a controlled allergen challenge.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIRCH POLLEN ALLERGY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cliantha Research
Mississauga, Ontario, ON L4W 1A4, Canada
Conditions
Explore the condition pages connected to this study.